

Didanosine

Catalog No: tcsc2229



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

69655-05-6

Formula:

$C_{10}H_{12}N_4O_3$

Pathway:

Anti-infection;Anti-infection

Target:

Reverse Transcriptase;HIV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 65 mg/mL (275.16 mM)

Alternative Names:

2',3'-Dideoxyinosine;ddl

Observed Molecular Weight:


236.23

Product Description

Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μ M.

Target: NRTIs; HIV

Didanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddl might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddl therapy [2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!